Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMO | Q99835 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CCKAR | P32238 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5760748 | 0.79 | ALDH1A1 (0.45) | ALDH1A1KDM4ELMNAGAAL3MBTL1 | |
| SCHEMBL6494942 | 0.75 | ALDH1A1 (0.51) | ALDH1A1KDM4ELMNAGAAL3MBTL1 | |
| SCHEMBL1381201 | 0.74 | ALDH1A1 (0.46) | ALDH1A1KDM4ELMNAGAAL3MBTL1 | |
| SCHEMBL5759703 | 0.73 | ALDH1A1 (0.46) | ALDH1A1KDM4ELMNAGAAL3MBTL1 | |
| SCHEMBL1380918 | 0.73 | LMNA (0.50) | ALDH1A1KDM4ELMNAGAAL3MBTL1 | |
| SCHEMBL6882152 | 0.73 | ALDH1A1 (0.59) | ALDH1A1KDM4ELMNAGAAL3MBTL1 | |
| SCHEMBL1381524 | 0.72 | POLB (0.52) | ALDH1A1KDM4ELMNAGAAL3MBTL1 | |
| SCHEMBL6497029 | 0.71 | ALDH1A1 (0.51) | ALDH1A1KDM4ELMNAGAAL3MBTL1 | |
| SCHEMBL1381703 | 0.71 | TP53 (0.53) | ALDH1A1KDM4ELMNAGAAL3MBTL1 | |
| SCHEMBL1384296 | 0.71 | LMNA (0.50) | ALDH1A1KDM4ELMNAGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4805813-B2 | — | — | 2011-11-02 | — | — | JP | claimed |
| EP-1641765-A1 | ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF | Aventis Pharma S.A. (FR) | 2006-04-05 | — | — | EP | claimed |
| US-20050014765-A1 | Aryl-heteroaromatic products, compositions comprising them and use | AVENTIS PHARMA S.A. (FR) | 2005-01-20 | — | — | US | claimed |
| WO-2004108685-A1 | ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2004-12-16 | — | — | WO | claimed |
| EP-1641765-A1 | ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF | Aventis Pharma S.A. (FR) | 2006-04-05 | — | — | EP | disclosed |
| US-20050059679-A1 | Novel hexacyclic compounds | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2005-03-17 | — | — | US | disclosed |
| US-20050014765-A1 | Aryl-heteroaromatic products, compositions comprising them and use | AVENTIS PHARMA S.A. (FR) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108685-A1 | ARYL-HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2004-12-16 | — | — | WO | disclosed |
| US-6825194-B2 | AN 11,12-(-N=C(=O,S OR NH)-NH-)CAMPTOTHECIN DERIVATIVE OR AN 11,12-(-N=CH-NH-)CAMPTOTHEDIN DERIVATIVE; ANTICARCINOGENIC, -TUMOR AND -PROLIFERATIVE AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-11-30 | — | — | US | disclosed |
| US-20030144304-A1 | Novel hexacyclic compounds | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059679-A1 | Novel hexacyclic compounds | CYP11B1, CYP11B2, CYP4A11 | ALDH1A1 720/4885KDM4E 3364/4885LMNA 2675/4885 |
| US-20050014765-A1 | Aryl-heteroaromatic products, compositions comprising them and use | AHR, ARNT, MYC | ALDH1A1 240/4885KDM4E 1246/4885LMNA 3596/4885 |
| US-20030144304-A1 | Novel hexacyclic compounds | CYP11B1, CYP11B2, CYP51A1 | ALDH1A1 499/4885KDM4E 3162/4885LMNA 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.